OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment

Oral Oncology

Volumn 52, Issue , 2016, Pages 1-10

  Bell, R Bryan ^a,b,c,d   Leidner, Rom S ^a,b   Crittenden, Marka R ^a,b   Curti, Brendan D ^a   Feng, Zipei ^a,c   Montler, Ryan ^a,c   Gough, Michael J ^a   Fox, Bernard A ^a,c   Weinberg, Andrew D ^a,c   Urba, Walter J ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Head and Neck Surgical Associates   (United States)

Author keywords

CTLA 4; Head and neck cancer; Immunotherapy; Oral cancer; OX40; PD 1

Indexed keywords

OX40 LIGAND; CD134 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TNFRSF4 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; CANCER IMMUNOTHERAPY; CANCER SURGERY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; HEAD AND NECK TUMOR; IMMUNOLOGY; METABOLISM; MOUSE; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CTLA-4 ANTIGEN; HEAD AND NECK NEOPLASMS; HUMANS; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, OX40; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84962425634     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2015.11.009     Document Type: Review

References (92)

1. American Cancer Society. Cancer facts and figures 2015. Atlanta: American Cancer Society; 2015.
2. A.K. Chaturvedi, E.A. Engels, W.F. Anderson, and M.L. Gillison Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States J Clin Oncol 26 2008 612 619
3. M.A. O'Rorke, M.V. Ellison, L.J. Murray, M. Moran, J. James, and L.A. Anderson Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis Oral Oncol 48 2012 1191 1201
4. L. Zitvogel, O. Kepp, and G. Kroemer Immune parameters affecting the efficacy of chemotherapeutic regimens Nat Rev Clin Oncol 8 2011 151 160
5. J. Kjaergaard, L. Peng, P.A. Cohen, J.A. Drazba, A.D. Weinberg, and S. Shu Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor J Immunol 167 11 2001 6669 6677
6. M.J. Gough, C.E. Ruby, W.L. Redmond, B. Dhungel, A. Brown, and A.D. Weinberg OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor Cancer Res 68 13 2008 5206 5215
7. B.D. Curti, M. Kovacsovics-Bankowski, N. Morris, E. Walker, L. Chisholm, and et al. OX40 is a potent immune-stimulating target in late stage cancer patients Cancer Res 73 2013 7189 7198
8. F. Pages, A. Berger, M. Camus, F. Sanchez-Cabo, A. Costes, and et al. Effector memory t cells, early metastasis, and survival in colorectal cancer N Engl J Med 353 25 2005 2654 2668
9. J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, and et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
10. L.V. Distel, and et al. Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease Oral Oncol 2009 45 2009 167 174
11. D. Wansom, E. Light, F. Worden, M. Prince, S. Urba, D.B. Chepeha, and et al. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer Arch Otolaryngol Head Neck Surg 136 12 2010 1267 1273
12. V.L. Green, A. Michno, N.D. Stafford, and J. Greenman Increased prevalence of tumour infiltrating immune cells in oropharyngeal tumours in comparison to other subsites: relationship to peripheral immunity Cancer Immunol Immunother 2013 10.1007/s00262-013-1395-9
13. M.J. Ward, S.M. Thirdborough, T. Mellows, C. Riley, S. Harris, and et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer Br J Cancer 110 2014 489 500
14. K. Chikamatsu, A. Albers, J. Stanson, W.W. Kwok, E. Appella, T.L. Whiteside, and et al. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor reactive CD8+ T cells Cancer Res 63 13 2003 3675 3681 1
15. A. Saha, R. Kaul, M. Murakami, and E.S. Robertson Tumor viruses and cancer biology: modulating signaling pathways for therapeutic intervention Cancer Biol Ther 10 10 2010 961 978
16. B.G. Bajaj, M. Murakami, and E.S. Robertson Molecular biology of EBV in relationship to AIDS-associated oncogenesis Cancer Treat Res 133 2007 141 162
17. M.P. Thompson, and R. Kurzrock Epstein-barr virus and cancer Clin Cancer Res 10 3 2004 803 821
18. G.D. Sckisel, M.N. Bouchlaka, A.M. Monjazeb, M. Crittenden, B.D. Curti, and et al. Out of sequence signal 3 paralyzes primary CD4(+) T-cell dependent immunity Immunity 43 2 2015 240 250 August 18
19. P.C. Tumeh, C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J.M. Taylor, and et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 2014 568 571
20. A.W. Turksma, B.J.M. Braakhuis, E. Bloemena, and et al. Immunotherapy for head and neck cancer patients: shifting the balance Immunotherapy 5 1 2013 49 61
21. M.G. Lechner, and et al. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines J Transl Med 9 2011 90
22. H.B. Jie, N. Gildener-Leapman, J. Li, R.M. Srivastava, S.P. Gibson, T.L. Whiteside, and et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients Br J Cancer 109 2013 2629 2635
23. K. Chikamatsu, and et al. Immunosuppressive activity of CD14+ HLA-DR-cells in squamous cell carcinoma of the head and neck Cancer Sci 103 2012 976 983
24. D. Vasquez-Dunddel, and et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients J Clin Invest 2013 10.1172/JCI60083
25. H.P. Jie, P.J. Schuler, S.C. Lee, R.M. Srivastava, A. Argiris, S. Ferrone, and et al. CTLA-4+ regulatory T cell increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis Cancer Res 75 11 2015 2200 2210 June 1
26. A.E. Albers, L. Strauss, T. Liao, T.K. Hoffmann, and A.M. Kaufmann T cell-tumor interaction directs the development of immunotherapies in head and neck cancer Clin Dev Immunol 2010 236 378
27. M. Czystowska, W. Gooding, M.J. Szczepanski, A. Lopez-Abaitero, R.L. Ferris, J.T. Johnson, and et al. The immune signature of CD8+CCR7+ T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC Clin Cancer Res 19 2013 889 899
28. P. Correale, M.S. Rotundo, C. Botta, M.T. Del Vecchio, and et al. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma Clin Cancer Res 18 2012 850 857
29. Z. Feng, T. Moudgil, A. Cheng, C. Paustian, R. vande Ven, C. Dubay, and et al. Utilizing quantitative immunohistochemistry for relationship analysis of tumor microenvironment of head and neck cancer patients J Immunother Cancer 2 Suppl 3 2014 258
30. J.K. Thurlow, and et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma J Clin Oncol 28 2010 2881 2888
31. C. Paustian, Z. Feng, T. Hulett, T. Moudgil, C. Dubay, M. Campbell, and et al. Recurrence of head and neck squamous cell cancer following resection may be predicted by assessment of immune infiltrates within the tumor J Immunol 194 1 supplement 2015 221 237 May 1
32. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 5256 1996 1734 1736 22
33. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
34. M. Maio, J.J. Grob, S. Aaamdal, I. Bondarenko, C. Robert, L. Thomas, and et al. Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial J Clin Oncol 33 10 2015 1191 1196
35. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
36. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
37. C. Robert, J. Schachter, G.V. Long, A. Arance, J.J. Grob, and et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 2015 April 19. Epub ahead of print
38. M. Postow, J. Chesney, A.C. Pavlick, C. Robert, K. Grossmann, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 2015 April 20. [epub ahead of print]
39. E.B. Garon, N.A. Rizvi, R. Hui, N. Leighi, A.S. Balmanoukian, and et al. Pembrolizumab for the treatment of non-small cell lung cancer N Engl J Med 2015 April 19 [epub ahead of print]
40. C. Robert, G.V. Long, B. Brady, C. Dutriaux, M. Maio, and et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 4 2015 320 330 January 22. [epub 2014 November 16]
41. C. Robert, A. Ribas, J.D. Wolchok, F.S. Hodi, O. Hamid, and et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial Lancet 384 9948 2014 1109 1117 September 20 [epub 2014 July 15]
42. J. Larkin, V. Chirarion-Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 1 2015 23 34 July 2. [epub 2015 May 31]
43. H. Borghaei, L. Paz-Ares, L. Horn, D.R. Spigel, M. Steins, and et al. Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer N Engl J Med 2015 September 27. [epub ahead of print]
44. T.Y. Seiwert, R.L. Haddad, S. Gupta, R. Mehra, M. Tahara, and et al. Antitumor activity and safety of pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck: preliminary results from KEYNOTE-012 expansion cohort J Clin Oncol suppl; abstr LBA6008 2015
45. D.P. Zandberg, A. Jarkowski, U.A. Emeribe, T. Goswami, and et al. A phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: HAWK (NCT02207530) J Clin Oncol 33 suppl; abstr TPS6086 2015
46. I. Melero, W.W. Shuford, S.A. Newby, A. Aruffo, J.A. Ledbetter, K.E. Hellstrom, and et al. Monoclonal antibodies against the 4-1BB T cell activation molecule eradicate established tumors Nat Med 3 1997 682 685
47. A.D. Weinberg, M.M. Rivera, R. Prell, A. Morris, and et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity J Immunol 164 2000 2160 2169
48. A.D. Weinberg, A.T. Vella, and M. Croft OX-40: life beyond the effector T cell stage Semin Immunol 10 6 1998 471 480
49. C.A. Chambers, M.S. Kuhns, J.G. Egen, and J.P. Allison CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy Annu Rev Immunol 19 2001 565 594
50. R.A. Prell, D.E. Evans, C. Thalhofer, T. Shi, C. Funatake, and A.D. Weinberg OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent J Immunol 171 11 2003 5997 6005
51. S.W. Lee, Y. Park, A. Song, H. Cheroutre, B.S. Kwon, and M. Croft Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses J Immunol 177 7 2006 4464 4472
52. W.L. Redmond, M.J. Gough, B. Charbonneau, T.L. Ratliff, and A.D. Weinberg Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist J Immunol 179 11 2007 7244 7253
53. K. Sugamura, N. Ishii, and A.D. Weinberg Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40 Nat Rev Immunol 4 2004 420 431
54. W.L. Redmond, and A.D. Weinberg Targeting OX40 and OX40L for the treatment of autoimmunity and cancer Crit Rev Immunol 27 5 2007 415 436
55. I. Gramaglia, A.D. Weinberg, M. Lemon, and M. Croft Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses J Immunol 161 12 1998 6510 6517
56. J.A. Kaleeba, H. Offner, A.A. Vandenbark, A. Lublinski, and A.D. Weinberg The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells Int Immunol 10 4 1998 453 461
57. W.L. Redmond, S.N. Linch, and M.J. Kasiewicz Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity Cancer Immunol Res 2 2 2014 142 153 10.1158/2326-6066
58. C. Cuadros, A.L. Dominguez, P.L. Lollini, M. Croft, R.S. Mittler, P. Borgstrom, and et al. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice Int J Cancer 116 6 2005 934 943
59. Z. Guo, X. Wang, D. Cheng, Z. Xia, M. Luan, and S. Zhang PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer PLoS One 9 2 2014 e89350
60. C.E. Ruby, R. Montler, R. Zheng, S. Shu, and A.D. Weinberg IL-12 is required for anti-OX40-mediated CD4 T cell survival J Immunol 180 4 2008 2140 2148
61. S.J. Lee, L. Myers, G. Muralimohan, J. Dai, Y. Qiao, Z. Li, and et al. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function J Immunol 173 5 2004 3002 3012 10.4049/jimmunol.173.5.3002
62. A. Morales-Kastresana, M.F. Sanmamed, I. Rodriguez, A. Palazon, I. Martinez-Forero, S. Labiano, and et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model Clin Cancer Res 19 22 2013 6151 6162
63. P.Y. Pan, Y. Zang, K. Weber, M.L. Meseck, and S.H. Chen OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases Mol Ther 6 4 2002 528 536
64. J.C. Gray, R.R. French, S. James, A. Al-Shamkhani, P.W. Johnson, and M.J. Glennie Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies Eur J Immunol 38 9 2008 2499 2511
65. J. Vercellini, C. Tucker, A. Moran, F. Polesso, and A. Weinberg Comparison of anti-OX40 to PD-1 and CTLA-4 blockade in T cell immunization/priming models J Immunol 194 1 Supplement 2015 70 74 May 1
66. A. Moran, F. Polesso, and A. Weinberg OX40 agonist immunotherapy expands tumor reactive CD8 T cells with a unique T cell receptor repertoire and synergizes with PDL-1 blockade to promote tumor regression J Immunother Cancer 2 Suppl 3 2014 018
67. M. Sen, S. Joyce, M. Panahandeh, C. Li, S.M. Thomas, J. Maxwell, and et al. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer Clin Cancer Res 18 18 2012 4986 4996 15
68. T.A. Triplett, C.G. Tucker, K.C. Triplett, Z. Alderman, L. Sun, L.E. Ling, and et al. STAT3 signaling is required for optimal regression of large established tumors in mice treated with anti-OX40 and TGF-beta receptor blockade Cancer Immunol Res 2015 January 27. Epub ahead of print
69. M.J. Gough, M.R. Crittenden, M. Sarff, P. Pang, S.K. Seung, J.T. Vetto, and et al. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control following surgical or radiation therapy of cancer in mice J Immunother 33 8 2010 798 809
70. A.A. Lugade, J.P. Moran, S.A. Gerber, R.C. Rose, J.G. Frelinger, and E.M. Lord Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor J Immunol 174 12 2005 7516 7523 June 15
71. L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, A. Criollo, and et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat Med 13 9 2007 1050 1059 September. Epub 2007 August 19
72. S.K. Seung, B. Curti, M. Crittenden, and W. Urba Radiation and immunotherapy: renewed allies in the war on cancer Oncoimmunology 1 9 2012 1645 1647
73. M.J. Gough, and M.R. Crittenden Immune system plays an important role in the success and failure of conventional cancer therapy Immunotherapy 4 2 2012 125 128
74. P. Yu, D.A. Rowley, Y.X. Fu, and H. Schreiber The role of stroma in immune recognition and destruction of well-established solid tumors Curr Opin Immunol 18 2006 226 231
75. S.K. Seung, B.D. Curti, M. Crittenden, E. Walker, T. Coffey, J.C. Siebert, and et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses Sci Transl Med 4 2012 137
76. E.A. Reits, J.W. Hodge, C.A. Herberts, T.A. Groothuis, M. Chakraborty, E.K. Wansley, and et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy J Exp Med 203 2006 1259 1271
77. S. Demaria, N. Kawashima, A.M. Yang, and et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer Clin Cancer Res 11 2005 728 734
78. L. Deng, H. Liang, B. Bernette, M. Beckett, T. Darga, R.R. Weichselbaum, and et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice J Clin Invest 124 2014 687 695
79. C. Twyman-Saint Victor, A.J. Rech, A. Maity, R. Rengan, K.E. Pauken, and et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Nature 520 7547 2015 373 377 April 16. Epub 2015 March 9
80. R.S. Leidner, S.P. Patel, M.G. Fury, R.L. Ferris, J.T. McDevitt, M.C. Lanasa, and et al. A phase I study to evaluate the safety, tolerability, PK, pharmacodynamics and preliminary clinical activity of MEDI0562 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 33 suppl; abstr TPS6083 2015
81. R. Montler, R.B. Bell, R. Leidner, T. Bui, A. Chang, A. Patel, and et al. OX40, PD-1 and CTLA-4 are selectively expressed on tumor infiltrating T cells in head and neck cancer Clin Trans Immunol 2015 [in press]
82. J.T. Vetto, S. Lum, A. Morris, M. Sicotte, J. Davis, M. Lemon, and et al. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers Am J Surg 174 3 1997 258 265
83. T. Ramstad, L. Lawnicki, J. Vetto, and A. Weinberg Immunohistochemical analysis f primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40 Am J Surg 179 5 2000 400 406
84. C.E. Ruby, M.A. Yates, D. Hirschhom-Cymerman, P. Chlebeck, J.D. Wolchok, A.N. Houghton, and et al. Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right J Immunol 183 8 2009 4853 4857 October 15
85. M.D. Vu, X. Xiao, W. Gao, N. Degauque, M. Chen, A. Kroemer, and et al. OX40 costimulation turns off Foxp3+ Tregs Blood 110 7 2007 2501 2510 October 1. Epub 2007 June 15
86. B. Valzasina, C. Guiducci, H. Disligh, N. Killeen, A.D. Weinberg, and M.P. Colombo Triggering of OX40 (CD137) on CD4+CD25+ T cells block their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR Blood 105 7 2005 2845 2851 April 1. Epub 2004 December 9
87. S. Piconese, B. Valzasina, and M.P. Colombo OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection J Exp Med 205 4 2008 825 839 14
88. E. Wakamatsu, D. Mathis, and C. Benoist Convergent and divergent effects of costimulatory molecules in conventional and regulatory CD4+ T cells Proc Natl Acad Sci USA 110 3 2013 1023 1028 January 15
89. T.R. Simpson, F. Li, W. Montalvo-Ortiz, M.A. Sepulveda, K. Bergenhoff, F. Arce, C. Roddie, and et al. Fc-dependent depletion of tumor infiltrating regulatory T cell co=defines the efficacy of anti-CTLA-4 therapy against melanoma J Exp Med 210 9 2013 1695 1710 August 26. Epub 2013 July 29
90. M.L. Gough, C.E. Ruby, W.L. Redmond, B. Dhungel, A. Brown, and A.D. Weinberg OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor Cancer Res 66 13 2008 5206 5215 July 1
91. Y. Bulliard, R. Jolicoeur, J. Zhang, G. Dranoff, N.S. Wilson, and J.L. Brogdon OX40 engagement depletes intratumoral Tregs via activating FcyRs, leading to antitumor efficacy Immunol Cell Biol 92 6 2014 475 480
92. S.F. Ngiow, A. Young, N. Jacquelot, T. Yamazaki, D. Enot, L. Zitvogel, and et al. A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1 Cancer Res 75 18 2015 3800 3811 September 15. Epub 2015 July 24